Jacobs Levy Equity Management’s Cytokinetics CYTK Stock Holding History

Jacobs Levy Equity Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50,570	Closed	-$1M	–	1054
2021 Q2	$1M	Buy	+50,570	New	+$1.19M	0.01%	740
2020 Q4	–	Sell	-113,330	Closed	-$2.45M	–	1030
2020 Q3	$2.45M	Sell	113,330 -135,877	-55%	-$3.18M	0.03%	484
2020 Q2	$5.87M	Sell	249,207 -449,545	-64%	-$8.43M	0.06%	307
2020 Q1	$8.24M	Buy	698,752 +187,022	+37%	+$2.39M	0.11%	207
2019 Q4	$5.43M	Buy	+511,730	New	+$5.26M	0.05%	354
2019 Q2	–	Sell	-219,736	Closed	-$1.78M	–	958
2019 Q1	$1.78M	Buy	219,736 +73,500	+50%	+$540K	0.03%	534
2018 Q4	$924K	Buy	146,236 +41,800	+40%	+$307K	0.02%	612
2018 Q3	$1.03M	Buy	104,436 +16,038	+18%	+$129K	0.01%	644
2018 Q2	$734K	Buy	88,398 +9,598	+12%	+$79.9K	0.01%	727
2018 Q1	$567K	Buy	+78,800	New	+$676K	0.01%	759
2017 Q3	–	Sell	-32,464	Closed	-$393K	–	961
2017 Q2	$393K	Buy	+32,464	New	+$451K	0.01%	731
2016 Q3	–	Sell	-22,130	Closed	-$210K	–	1037
2016 Q2	$210K	Sell	22,130 -51,957	-70%	-$426K	﹤0.01%	1000
2016 Q1	$522K	Sell	74,087 -9,400	-11%	-$68.7K	0.01%	713
2015 Q4	$873K	Sell	83,487 -29,500	-26%	-$289K	0.02%	465
2015 Q3	$756K	Buy	112,987 +42,241	+60%	+$288K	0.02%	524
2015 Q2	$475K	Sell	70,746 -45,500	-39%	-$298K	0.01%	576
2015 Q1	$788K	Sell	116,246 -106,535	-48%	-$796K	0.01%	526
2014 Q4	$1.78M	Buy	222,781 +111,335	+100%	+$478K	0.03%	404
2014 Q3	$392K	Buy	+111,446	New	+$468K	0.01%	637
2014 Q2	–	Sell	-182,100	Closed	-$1.73M	–	851
2014 Q1	$1.73M	Buy	182,100 +55,670	+44%	+$504K	0.03%	427
2013 Q4	$822K	Buy	126,430 +82,215	+186%	+$540K	0.01%	619
2013 Q3	$335K	Sell	44,215 -166	-0.4%	-$1.78K	0.01%	770
2013 Q2	$513K	Buy	+44,381	New	+$350K	0.01%	724

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jacobs Levy Equity Management's CYTK Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Cytokinetics (CYTK) in Q3 2021, closing a stake of 50,570 shares — an estimated $1M sold.

Jacobs Levy Equity Management first reported a position in CYTK in Q2 2013 and held it in 23 quarters. The position peaked at $8.24M in Q1 2020. 211 funds tracked by Wall St. Rank hold CYTK as of Q3 2021.

Jacobs Levy Equity Management reported no remaining Cytokinetics position as of Q3 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 50,570 Cytokinetics shares in Q3 2021, an estimated $1M.
Jacobs Levy Equity Management first reported a position in Cytokinetics in Q2 2013 and held it in 23 quarters.
Jacobs Levy Equity Management's Cytokinetics position peaked at $8.24M in Q1 2020.
211 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.